JO3227B1 - مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان - Google Patents

مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان

Info

Publication number
JO3227B1
JO3227B1 JOP/2012/0253A JOP20120253A JO3227B1 JO 3227 B1 JO3227 B1 JO 3227B1 JO P20120253 A JOP20120253 A JO P20120253A JO 3227 B1 JO3227 B1 JO 3227B1
Authority
JO
Jordan
Prior art keywords
deriveatives
piperazine
antipsychotic agents
substituted benzothiophene
superior
Prior art date
Application number
JOP/2012/0253A
Other languages
English (en)
Inventor
Minowa Takuya
Miyamoto Motoyuki
Kuroda Hideaki
Yamashita Hiroshi
Sakurai Yohji
Nakamura Yuichi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of JO3227B1 publication Critical patent/JO3227B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بمركب حلقي غير متجانس فائق جديد له قابلية مُحسنة للذوبان في الزيت مثل زيت السمسم وبنزوات البنزيل، والذي يكون له نطاق علاج واسع، ويتسبب في تأثيرات جانبية أقل، ويعتبر أفضل من حيث التحمل والأمان، واستخدامه، كما يتعلق الاختراع بمركب حلقي غير متجانس يتم التعبير عنه بواسطة الصيغة (I) حيث تم تعريف كل رمز في الوصف الكامل ، أو ملح منه.
JOP/2012/0253A 2011-09-08 2012-09-06 مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان JO3227B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161532393P 2011-09-08 2011-09-08

Publications (1)

Publication Number Publication Date
JO3227B1 true JO3227B1 (ar) 2018-03-08

Family

ID=46940565

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0253A JO3227B1 (ar) 2011-09-08 2012-09-06 مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان

Country Status (31)

Country Link
US (9) US9260420B2 (ar)
EP (1) EP2753617B9 (ar)
JP (1) JP6193848B2 (ar)
KR (1) KR101998441B1 (ar)
CN (1) CN103781783B (ar)
AR (1) AR087809A1 (ar)
AU (1) AU2012305212B2 (ar)
BR (1) BR112014005235B1 (ar)
CA (1) CA2847339C (ar)
CO (1) CO6930362A2 (ar)
CY (1) CY1118753T1 (ar)
DK (1) DK2753617T3 (ar)
EA (1) EA028160B1 (ar)
ES (1) ES2572934T3 (ar)
HR (1) HRP20160824T2 (ar)
HU (1) HUE027746T2 (ar)
IL (1) IL231116B (ar)
JO (1) JO3227B1 (ar)
MX (1) MX359515B (ar)
MY (1) MY196864A (ar)
PH (1) PH12014500496A1 (ar)
PL (1) PL2753617T3 (ar)
PT (1) PT2753617T (ar)
RS (1) RS54894B9 (ar)
SG (2) SG10201601731RA (ar)
SI (1) SI2753617T1 (ar)
SM (1) SMT201600205B (ar)
TW (1) TWI568728B (ar)
UA (1) UA112993C2 (ar)
WO (1) WO2013035892A1 (ar)
ZA (1) ZA201401433B (ar)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JP2014196292A (ja) * 2013-03-07 2014-10-16 大塚製薬株式会社 医薬
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
CN109716411B (zh) * 2016-09-08 2021-06-25 福特汽车公司 用以监测驾驶员的活动水平的方法和设备
CN111233848A (zh) * 2016-12-14 2020-06-05 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
US20180265472A1 (en) * 2017-03-17 2018-09-20 Scinopharm Taiwan, Ltd. Process for preparing aripiprazole lauroxil and intermediates thereof
CN107628999B (zh) * 2017-10-25 2019-07-02 苏州华健瑞达医药技术有限公司 阿立哌唑十二烷酸酯的制备方法
CN109988162A (zh) * 2017-12-29 2019-07-09 武汉兴华智慧医药科技有限公司 一种依匹哌唑衍生物及其制备方法
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
CN108947990A (zh) * 2018-07-20 2018-12-07 成都苑东生物制药股份有限公司 一种苯并噻吩类化合物的制备方法
DK3908570T3 (da) * 2019-01-11 2024-02-26 Alar Pharmaceuticals Inc Ketaminpamoat og andevendelse deraf
AU2021305165A1 (en) 2020-07-06 2023-02-02 Tactogen Inc Advantageous benzothiophene compositions for mental disorders or enhancement
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
CN114044772A (zh) * 2021-11-29 2022-02-15 浙江国邦药业有限公司 一种依匹哌唑合成方法及其中间体
CN116407539B (zh) * 2021-12-30 2025-01-10 上海现代药物制剂工程研究中心有限公司 依匹哌唑甲基脂肪酸酯的用途
CN116410186B (zh) * 2021-12-30 2025-03-04 上海现代药物制剂工程研究中心有限公司 依匹哌唑甲基脂肪酸酯及其制备方法
EP4501926A4 (en) * 2022-03-30 2025-06-25 Vigonvita Life Sciences Co., Ltd. N-substituted quinolinone compound, preparation method therefor and use thereof
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤
EP4673217A1 (en) * 2023-02-27 2026-01-07 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
TW202448427A (zh) 2023-05-02 2024-12-16 日商大塚製藥股份有限公司 雜環化合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12923A (en) 2002-09-17 2006-10-13 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
RU2356554C2 (ru) 2002-12-27 2009-05-27 Оцука Фармасьютикал Ко., Лтд. Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20050254575A1 (en) 2004-05-12 2005-11-17 Nokia Corporation Multiple interoperability points for scalable media coding and transmission
DE102004031052A1 (de) 2004-06-25 2006-01-12 Bühler AG System und Verfahren zur Mahlgut-Charakterisierung in einem Walzenstuhl
EP1798328A4 (en) 2004-07-29 2009-07-15 Magie Pression Co Ltd METHOD FOR PLEATING A FABRIC COMPRISING A POLYLACTIC ACID YARN AND PLEATED TISSUE
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
WO2006111246A1 (de) 2005-04-18 2006-10-26 Loi Thermprocess Gmbh Industrieofen
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
AU2010266018B2 (en) * 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8686009B2 (en) * 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
CA2798172C (en) 2010-01-07 2017-11-21 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CA2822447C (en) 2010-12-23 2018-05-01 Alkermes Pharma Ireland Limited Multi-api loading prodrugs
MX358344B (es) 2011-03-18 2018-08-15 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan.
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان

Also Published As

Publication number Publication date
HRP20160824T2 (hr) 2017-05-19
MY196864A (en) 2023-05-05
US9260420B2 (en) 2016-02-16
WO2013035892A1 (en) 2013-03-14
CY1118753T1 (el) 2017-07-12
CA2847339C (en) 2020-03-10
EP2753617A1 (en) 2014-07-16
US20200061056A1 (en) 2020-02-27
US20170071933A1 (en) 2017-03-16
JP6193848B2 (ja) 2017-09-06
SI2753617T1 (sl) 2016-08-31
SG10201601731RA (en) 2016-04-28
KR20140069109A (ko) 2014-06-09
BR112014005235B1 (pt) 2022-03-29
TWI568728B (zh) 2017-02-01
US20160143905A1 (en) 2016-05-26
RS54894B1 (sr) 2016-10-31
AR087809A1 (es) 2014-04-16
ZA201401433B (en) 2015-05-27
SG11201400148QA (en) 2014-03-28
MX359515B (es) 2018-10-01
IL231116A0 (en) 2014-04-30
EA201490585A1 (ru) 2014-08-29
US20150045356A1 (en) 2015-02-12
RS54894B9 (sr) 2019-12-31
US20190167672A1 (en) 2019-06-06
PT2753617T (pt) 2016-07-13
PH12014500496A1 (en) 2014-04-14
KR101998441B1 (ko) 2019-07-09
CN103781783A (zh) 2014-05-07
ES2572934T3 (es) 2016-06-03
EP2753617B1 (en) 2016-04-13
CO6930362A2 (es) 2014-04-28
AU2012305212A1 (en) 2014-04-24
PL2753617T3 (pl) 2016-10-31
EA028160B1 (ru) 2017-10-31
BR112014005235A2 (pt) 2017-04-11
NZ621837A (en) 2015-06-26
DK2753617T3 (en) 2016-07-25
HUE027746T2 (en) 2016-10-28
IL231116B (en) 2019-09-26
EP2753617B9 (en) 2017-01-25
US20230099694A1 (en) 2023-03-30
HK1195550A1 (zh) 2014-11-14
US9539252B2 (en) 2017-01-10
UA112993C2 (uk) 2016-11-25
CN103781783B (zh) 2016-12-07
SMT201600205B (it) 2016-08-31
JP2014526435A (ja) 2014-10-06
US20210052575A1 (en) 2021-02-25
US20180092907A1 (en) 2018-04-05
TW201326160A (zh) 2013-07-01
MX2014002254A (es) 2014-04-30
US20180318294A1 (en) 2018-11-08
HRP20160824T1 (hr) 2016-08-26
CA2847339A1 (en) 2013-03-14
ES2572934T9 (es) 2017-05-08
AU2012305212B2 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
JO3227B1 (ar) مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
MY171055A (en) 3,5-disubstituted alkynylbenzene compound and salt thereof
MX2015002040A (es) Baricitinib deuterado.
EA201290800A1 (ru) Гетероциклическое соединение
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
IN2015DN01035A (ar)
MX2015001246A (es) Ibrutinib deuterado.
PH12014502169A1 (en) N-cyclylamides as nematicides
TN2015000245A1 (en) Heterocyclic compound
MX2011007998A (es) Nuevos herbicidas.
MX2010002243A (es) Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida.
MY161132A (en) Novel herbicides
IN2012DE00621A (ar)
MX2011007932A (es) Herbicidas nuevos.
IN2012DE00620A (ar)
PH12015502665A1 (en) Improvements in or relating to organic compounds
TN2011000355A1 (en) Novel microbiocides
IN2014MN01637A (ar)
IN2012DN00773A (ar)
PH12015501146A1 (en) Hydantoin derivative
IN2014DN10669A (ar)
IN2012DN01223A (ar)
NZ707308A (en) Malononitrile compounds for controlling animal pests
MX2015007568A (es) Compuestos de malononitrilo para controlar plagas de animales.
UA79866U (ru) Применение 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с антидепрессивным действием